Amphotericin B: The end of an era;Amfotericine B: Het einde van een tijdperk

Nederlands Tijdschrift voor Geneeskunde

Volumn 148, Issue 34, 2004, Pages 1665-1668

  Lashof, A M L Oude ^a   Kullberg, B J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INFUSION; FUNGAL MENINGITIS; HUMAN; MYCOSIS; NEPHROTOXICITY; REVIEW; TOXICITY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG CARRIERS; HUMANS; MYCOSES; TREATMENT OUTCOME;

EID: 4344697234     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Rex JH, Bennett JE, Sugar AM, Pappas PG, Horst CM van der, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331:1325-30.
2. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66.
4. Wout JW van 't, Kuijper EJ, Verweij PE, Kullberg BJ. Nieuwe ontwikkelingen in de antifungale therapie: fluconazol, itraconazol, voriconazol, caspofungine. Ned Tijdschr Geneeskd 2004;148:1679-84.
5. Ellis M, Spence D, Pauw B de, Meunier F, Marinus A, Collette L, et al. An EORTC international multicenter randomized trial (EORTC nr 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27: 1406-12.
6. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-8.
7. Hamill RJ, Sobel JD, El-Sadr W, Johnson P, Graybill JR, Javaly K, et al. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients [abstract 1161]. In: 39th Interscience Conference on antimicrobial agents and chemotherapy, 1999. San Francisco, Calif.: American Society of Microbiology; 1999. P. 490.
8. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21.
9. Anaissie EJ, White MH, Uzun O, Singer C, Bodey GP, Azarnia N, et al. Amphotericin B lipid complex versus amphotericin B for treatment of invasive candidiasis: a prospective, randomized multicenter trial [abstract LM21]. In: 35th Interscience Conference on antimicrobial agents and chemotherapy, 1995. Washington, D.C.: American Society of Microbiology; 1995.
10. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-71.
11. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-12.
12. Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66.
13. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002;137:105-9.
14. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71.
15. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/-ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63.
16. White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302.
17. Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25:1295-320.
18. Bow EE, Laverdiere M, Rotstein C. A systemic review of the efficacy of azoles and lipid-based formulations of amphotericin B as empirical antifungal therapy in persistently febrile neutropenic patients despite broad-spectrum antibacterial therapy [abstract 702]. In: 40th Interscience Conference on antimicrobial agents and chemotherapy, 2000. Washington, D.C.: American Society of Microbiology; 2000.
19. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7.
20. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93.
21. Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002;35:e120-7.
22. Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000;18:2476-83.
23. Kullberg BJ, Pappas P, Ruhnke M, Viscoli C, Rex JH, Schlamm H, et al. Voriconazole compared to a strategy of amphotericin B followed by fluconazole for treatment of candidemia in non-neutropenic patients. Clin Microb Infect 2004;10(Suppl 3):S41.
24. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15.
25. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000;30:696-709.
26. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
27. Walsh T, Sable C, Pauw B de, Donowitz G, Maertens J, Baden L, et al. A randomized, double-blind, multicenter trial of caspofungin versus liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients [abstract M-1761]. Washington, D.C.: American Society of Microbiology; 2003.
28. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950-2.
29. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-8.
30. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004;38:377-83.